In New Jersey, the number of Benicar lawsuits filed between the months of June and July of 2015 increased dramatically. The suits come from patients who suffered adverse reactions from having taken the drug Benicar to treat hypertension.
The number of consolidated lawsuits scheduled for pretrial proceedings in MDL 2606 has now reached over 1000 cases, The lawsuits were consolidated because they all have similar questions of fact rather than as an indication as to the merits of a lawsuit brought by plaintiffs. The cases are all similar in that they allege that drug maker, Daiichi Sankyo Inc. and Forest Laboratories Inc. failed to adequately warn both physicians and consumers about the potential risks of developing sprue-like enteropathy after having taken Benicar.
Benicar, otherwise known by its generic name of Olmesartan, is used to treat patients with hypertension or high blood pressure. Lawsuits allege that patients developed sprue-like enteropathy – marked by severe diarrhea and weight loss after using Benicar and were filed after an announcement in July of 2013 by the FDA that Benicar was potentially linked to patients developing sprue-like enteropathy. The agency noted that there was “clear evidence of an association between olmesartan and sprue-like enteropathy.”
The FDA issued its warning after identifying 23 serious cases of sprue-like enteropathy linked to Benicar in the FDA Adverse Event Reporting System. At the time, the FDA approved changes to Benicar’s label to warn about the potential for sprue-like enteropathy.
The cases are still in the beginning stages. However, it is believed that given the popularity of the drug to treat high blood pressure in patients, there is a high probability of more lawsuits being filed against the manufacturers of Benicar. If you believe you were harmed by Benicar, call us for more information.